Navigation Links
Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
Date:9/18/2007

TOKYO, September 18 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announces that AD 337, an enantiomer of an approved, centrally acting, non-opioid, analgesic, has completed a Phase II proof of principle trial for the treatment of fibromyalgia syndrome (FMS).

The trial, a multi-centre, randomised, double-blind, placebo controlled, parallel group exploratory study, investigated the efficacy, safety and tolerability of AD 337 in the treatment of fibromyalgia in female subjects. In total, the trial enrolled 103 patients across 18 centres in the UK and Australia with the primary study endpoint being the difference in the Fibromyalgia Impact Questionnaire (FIQ) score, between active and placebo, after 4 weeks of treatment.

Results show that the study did not achieve a statistically significant outcome in its primary endpoint at 4 weeks. However statistical significance in FIQ was achieved at the 1 week time point and positive trends were seen throughout the study. In addition statistically significant measures in other efficacy assessments such as the Short Form McGill Pain Questionnaire and the Fibromyalgia Health Assessment Questionnaire (FHAQ) were seen at early time points. On balance it is concluded that AD 337 has some potential in the treatment of fibromyalgia syndrome.

AD 337 was well tolerated and there were no clinically significant changes in vital signs, biochemistry, haematology and cardiovascular parameters.

Commenting on these results Shinichi Tamura, CEO, said "This proof of principle study with an unoptimised formulation and dosing schedule and limited to four weeks in duration has demonstrated a degree of activity. Sosei will be evaluating these results to determine its approach to the possible further development of AD 337 in FMS and other potential indications."

Notes to Editors:

About Sosei

Sosei Group Corporation is a leading
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ... capital and general corporate purposes. Under ...
(Date:12/24/2014)... 2014 “Preparative & Process Chromatography ... Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, ... - Forecasts to 2019” provides a detailed overview ... market trends, and strategies impacting the preparative and ... forecasts of the revenue and share analysis. ...
(Date:12/24/2014)... Boston, MA (PRWEB) December 23, 2014 ... presentation, Dr. James L. Sherley, director of the Adult ... attention on an often overlooked and under appreciated unique ... “Asymmetric Self-Renewal by Distributed Stem Cells: Misunderstood in the ... his message to congress participants. He gave the ...
(Date:12/24/2014)... 2014 On Friday, December 19, ... the Omnibus and Continuing Resolution Appropriations Act of ... a condition eligible to receive funding through the ... the Department of Defense (DoD). The Hydrocephalus Association ... Capitol Hill, is celebrating this victory for the ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... Aug. 17 Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ... letter from the U.S. Food and Drug Administration ... for intravesical,instillation, is the only product approved by ... in situ (CIS) of the,urinary bladder. VALSTAR ...
... Accessing Technologies and ... a Decade, ST. LOUIS, Aug. 17 Monsanto ... National Biosafety,Technical Committee (CTNBio) approved the company,s MON 810 ... Corn Borer,for future commercial use in corn in Brazil. ...
... CIPH ) announced that on August 15, 2007 ... indicated the Company,is not in compliance with Marketplace Rule ... $2,500,000 in stockholders, equity; (ii) $35,000,000,market value of listed ... for the most recently completed fiscal year or two ...
Cached Biology Technology:Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 2Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 3Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 4Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait 2
(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
(Date:12/10/2014)... DUBLIN , Dec. 08, 2014 Research ... announced the addition of the "Biometrics Market ... http://photos.prnewswire.com/prnh/20130307/600769 ... for projects such as rural banking and upgradation ... major trends witnessed in the market. Besides the ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a leader ... million in Series A1 funding led by UK-based Eurovestech. ... participated in the investment round. "We are ... community adopts next-generation sequencing and seeks new approaches for ... Reid Robison , MD MBA, and CEO of Tute ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... of stress-related proteins that explains how plants avoid sunburn in ... to develop crops that can better cope with hotter, drier ... week in the journal PNAS . The ... early response of Arabidopsis to excess light," was ...
... URBANA, Ill. There was bad news, then good ... In the first study, they learned that frozen broccoli ... in fresh broccoli. But a second study demonstrated how ... vegetable,s health benefits. "We discovered a technique that ...
... Signal Hill, CA Tom Bowman, climate science communications expert ... economist Chris Hope and oceanographer Peter Wadhams, two of the ... that has stirred scientific controversy since its release on ... a single phenomenon of global warming in the Arctic ...
Cached Biology News:Dartmouth-led team discovers how plants avoid sunburn 2Illinois scientists put cancer-fighting power back into frozen broccoli 2
... nmol (individual) with sequence siTrio siRNA ... to your target gene of interestis our most ... more than 75% knockdown of your target gene ... for transfection and confirmation of optimal transfection with ...
The Bio-Plex Manager version 3.0 to 4.0 workstation software upgrade kit is used to upgrade existing Bio-Plex Manager version 3.0 software to version 4.0 security edition software....
... rigid macroporous hydrophilic media. The rigid polymer ... pressures, while the macroporous beads enhance access ... reduces nonspecific binding. Macro-Prep High Q support ... very high flow rates and resolution. It ...
... --- a cocktail of 3 siRNAs specifically ... our most popular product. The siTrio reagent ... of your target gene when used under ... and confirmation of optimal transfection with one ...
Biology Products: